TDC
ONCE

Thompson Davis & Co’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Thompson Davis & Co’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,000
Closed -$50K – 1282
2016
Q4 		$50K Hold
1,000
– – 0.08% 240
2016
Q3 		$60K Hold
1,000
– – 0.11% 203
2016
Q2 		$51K Buy
+1,000
New +$42.7K 0.08% 236

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return

Thompson Davis & Co's ONCE Position: Q1 2017 in Review

Thompson Davis & Co sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q1 2017, closing a stake of 1,000 shares — an estimated $50K sold.

Thompson Davis & Co first reported a position in ONCE in Q2 2016 and held it in 3 quarters. The position peaked at $60K in Q3 2016. 122 funds tracked by Wall St. Rank hold ONCE as of Q1 2017.

  • Thompson Davis & Co reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 1,000 Spark Therapeutics, Inc. Common Stock shares in Q1 2017, an estimated $50K.
  • Thompson Davis & Co first reported a position in Spark Therapeutics, Inc. Common Stock in Q2 2016 and held it in 3 quarters.
  • Thompson Davis & Co's Spark Therapeutics, Inc. Common Stock position peaked at $60K in Q3 2016.
  • 122 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q1 2017.

Based on Thompson Davis & Co's 13F filing for Q1 2017, filed 8 May 2017.